Objective:

To evaluate the long-term outcomes of MDMA-assisted psychotherapy for the treatment of post-traumatic stress disorder (PTSD).

Approach:

• Study Design: Longitudinal pooled analysis of six Phase 2 trials.

Key Findings:

• Significant reductions in PTSD symptom severity were reported.
• 67% of participants no longer met PTSD diagnostic criteria at final assessment.

Interpretation:

Limitations:

• Protocol violations at one study site (MP4) were not disclosed.
• Data from the compromised site was included in the analysis.
• Authors failed to fully declare potential conflicts of interest.
• The lack of disclosure regarding the ethical violations raises concerns about the study's integrity.

Conclusion:

The retraction emphasizes the importance of ethical guidelines and transparency in research.

Sources:

• Original study
• Retraction notice